Technical Analysis for GLYC - GlycoMimetics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical GLYC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jul 19 | Bullish Engulfing | Bullish | 0.00% |
| Jul 18 | Hammer Candlestick | Bullish | 3.58% |
| Jul 18 | Lizard Bullish | Bullish Day Trade Setup | 3.58% |
| Jul 18 | Doji - Bullish? | Reversal | 3.58% |
| Jul 16 | Downside 200 DMA Break | Bearish | 3.71% |
| Jul 16 | Overbought Stochastic | Strength | 3.71% |
| Jul 13 | 50 DMA Resistance | Bearish | -3.74% |
| Jul 13 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.74% |
| Jul 13 | Upside 200 DMA Break | Bullish | -3.74% |
| Jul 13 | Overbought Stochastic | Strength | -3.74% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-08-02
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more GLYC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 26.05 |
| 52 Week Low | 10.06 |
| Average Volume | 536,532 |
| 200-Day Moving Average | 17.0104 |
| 50-Day Moving Average | 17.0366 |
| 20-Day Moving Average | 15.974 |
| 10-Day Moving Average | 16.566 |
| Average True Range | 0.7914 |
| ADX | 16.23 |
| +DI | 20.3847 |
| -DI | 22.8772 |
| Chandelier Exit (Long, 3 ATRs ) | 14.8758 |
| Chandelier Exit (Short, 3 ATRs ) | 16.5842 |
| Upper Bollinger Band | 17.5042 |
| Lower Bollinger Band | 14.4438 |
| Percent B (%b) | 0.67 |
| BandWidth | 19.158633 |
| MACD Line | -0.1044 |
| MACD Signal Line | -0.1724 |
| MACD Histogram | 0.068 |
| Fundamentals | Value |
|---|---|
| Market Cap | 539.27 Million |
| Num Shares | 32.7 Million |
| EPS | -1.34 |
| Price-to-Earnings (P/E) Ratio | -12.30 |
| Price-to-Sales | 18873.21 |
| Price-to-Book | 3.02 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.79 | ||||
| Resistance 3 (R3) | 17.66 | 17.09 | 17.57 | ||
| Resistance 2 (R2) | 17.09 | 16.76 | 17.16 | 17.49 | |
| Resistance 1 (R1) | 16.79 | 16.56 | 16.94 | 16.92 | 17.42 |
| Pivot Point | 16.22 | 16.22 | 16.30 | 16.29 | 16.22 |
| Support 1 (S1) | 15.92 | 15.89 | 16.07 | 16.05 | 15.54 |
| Support 2 (S2) | 15.35 | 15.69 | 15.42 | 15.47 | |
| Support 3 (S3) | 15.05 | 15.35 | 15.39 | ||
| Support 4 (S4) | 15.18 |
